← Leaderboards
Saumya Das
Massachusetts General Hospital
$14,341,004
Attributed
$24,675,338
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,675,338 · 12
By mechanism
R01$6,278,590 · 3
R35$5,790,786 · 1
UH3$5,408,536 · 2
U01$3,664,508 · 1
UH2$1,074,150 · 1
UG3$938,561 · 1
Top collaborators
- Anthony Rosenzweig11 shared
- Raymond Y Kwong9 shared
- Marc S Sabatine9 shared
- Rohit N. Kulkarni8 shared
- Juan Dominguez-Bendala4 shared
- Ravi Shah4 shared
- Tijana Talisman4 shared
- Kendall R Van Keuren-Jensen4 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Anat Olga Stemmer-Rachamimov$1,001,767
- Davide Trotti$10,648,257
- Hyungsoon Im$5,025,374
- David J Milan$6,100,897
- Cuiyan Xin$82,939
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCardiacResearch PersonnelMorbidity - Disease RateTranscriptome SequencingTissuesInsightBiological MarkersPlasmaBaseLeadHeart FailurePhenotypeHeartCardiovascular DiseasesIn VivoExtracellular VesiclesSignal TransductionTherapeutic TargetMyocardial InfarctionCardiac MyocytesPathogenesisIn VitroResponse
Grant awards (43)
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$966,780
R35 · FY2025 · HL · contact PI
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk$882,433
U01 · FY2025 · DK
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease$708,815
R01 · FY2025 · DK · contact PI
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$951,669
R35 · FY2024 · HL · contact PI
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk$904,104
U01 · FY2024 · DK
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease$718,009
R01 · FY2024 · DK · contact PI
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$949,270
R35 · FY2023 · HL · contact PI
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk$919,535
U01 · FY2023 · DK
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease$753,720
R01 · FY2023 · DK · contact PI
Engineering RNA editing tools for the generation of functional tRNA-derived small RNAs in the kidney$331,754
R21 · FY2023 · DK · contact PI
Molecular dissection and imaging of extracellular vesicles to define their origin and targets$1,100,398
UH3 · FY2022 · TR · contact PI
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$977,000
R35 · FY2022 · HL · contact PI
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk$958,436
U01 · FY2022 · DK
Characterization of beta-cell-specific extracellular vesicle cargo as functional biomarkers for type I DM disease$820,000
R01 · FY2022 · DK · contact PI
Molecular dissection and imaging of extracellular vesicles to define their origin and targets$1,100,083
UH3 · FY2021 · TR · contact PI
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$985,397
R35 · FY2021 · HL · contact PI
Functional role and therapeutic targeting of exosomes and extracellular RNA biomarkers in heart failure$960,670
R35 · FY2020 · HL · contact PI
Molecular dissection and imaging of extracellular vesicles to define their origin and targets$454,882
UG3 · FY2020 · TR · contact PI
Novel Therapy for Long QT Syndrome$567,128
R01 · FY2019 · HL · contact PI
Molecular dissection and imaging of extracellular vesicles to define their origin and targets$483,679
UG3 · FY2019 · TR · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$434,998
R01 · FY2019 · HL · contact PI
Novel Therapy for Long QT Syndrome$599,237
R01 · FY2018 · HL · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$411,672
R01 · FY2018 · HL · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2017 · TR · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$411,672
R01 · FY2017 · HL · contact PI
Multi-group collaborative proposal: Diversity and function of prevalent uncharacterized exRNA species from tissue and biofluid$77,805
UH3 · FY2017 · TR · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2016 · TR · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$255,973
R01 · FY2016 · HL · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$155,700
R01 · FY2016 · HL · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$43,250
UH3 · FY2016 · TR · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$1,000,000
UH3 · FY2015 · TR · contact PI
Novel Role for Circulating extracellular RNAs in Human Heart Failure$441,666
R01 · FY2015 · HL · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$87,000
UH3 · FY2015 · TR · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$500,000
UH2 · FY2014 · TR · contact PI
Optimization of biofluid ex-RNA isolation and characterization.$74,150
UH2 · FY2014 · TR · contact PI
Plasma miRNA predictors of adverse mechanical and electrical remodeling after MI$500,000
UH2 · FY2013 · TR · contact PI
Molecular mechanisms of electrical remodeling in cardiac hypertrophy$136,350
K08 · FY2012 · HL · contact PI
Computational discovery of SGK1 inhibitors for the treatment of heart disease$289,359
R21 · FY2011 · HL
Molecular mechanisms of electrical remodeling in cardiac hypertrophy$136,350
K08 · FY2011 · HL · contact PI
Computational discovery of SGK1 inhibitors for the treatment of heart disease$217,344
R21 · FY2010 · HL
Molecular mechanisms of electrical remodeling in cardiac hypertrophy$136,350
K08 · FY2010 · HL · contact PI
Molecular mechanisms of electrical remodeling in cardiac hypertrophy$136,350
K08 · FY2009 · HL · contact PI
Molecular mechanisms of electrical remodeling in cardiac hypertrophy$136,350
K08 · FY2008 · HL · contact PI